WARF Therapeutics leverages an array of solutions to move validated targets to a high value developed chemical asset complete with a compelling preclinical data package.

Funding options available for new programs accepted into our portfolio include:

1. Stage 0 Target Validation

New programs accepted by the Scientific Advisory Board will be eligible for a one-time grant of $75K to validate a target in a disease context. If the target validation data is promising, the PI will then be asked to submit an application for Stage 1 drug discovery resourcing.

2. Stage 1 Drug Discovery

New programs accepted by the Scientific Advisory Board will be eligible for a one-time grant of $50K to further their independent research on the accepted target.